三肽-3 铜 AHK-Cu

AHK-Cu is a copper-binding tripeptide — specifically L-alanyl-L-histidyl-L-lysine complexed with a Cu²⁺ ion — that's attracted attention in skin biology and hair research for its ability to activate fibroblasts and influence how the body builds and remodels connective tissue. It's a close structural cousin to GHK-Cu, the better-studied copper peptide, but with alanine substituted for glycine at the first position. That single amino acid swap changes its behavior enough to make it worth studying on its own terms.

The research is still early. Everything published so far comes from cell culture and tissue studies — no human clinical trials have been completed, and the compound carries no FDA approval for any medical use. What the preclinical data does show is genuinely interesting: AHK-Cu appears to push fibroblasts toward repair and regeneration rather than scarring, and it shows early promise for hair follicle stimulation in ex vivo human tissue models.^[1]

If you're looking at AHK-Cu, you're probably either a researcher, a formulator working on topical cosmeceuticals, or someone who's already familiar with copper peptides and wants to understand how this one compares. This page covers what the science actually shows — and where the gaps are.

• AHK-Cu is a synthetic tripeptide copper complex studied for collagen synthesis, extracellular matrix remodeling, and hair follicle stimulation — not an FDA-approved drug.

Most copper peptides in the research literature follow the GHK-Cu framework — glycyl-L-histidyl-L-lysine has been studied since the 1970s and has a meaningful body of published work behind it. AHK-Cu is structurally distinct: replacing glycine with alanine at the N-terminus changes the peptide's steric profile and may affect how it interacts with cell surface receptors and copper transport proteins.^[1]

What the 2007 Archives of Pharmacal Research study found is that AHK-Cu behaves like a growth signal for dermal fibroblasts and dermal papilla cells — the specialized fibroblasts that control hair follicle cycling.^[1] It stimulated fibroblast proliferation, boosted VEGF (vascular endothelial growth factor, which supports new blood vessel formation around follicles), and — this part is worth paying attention to — reduced TGF-β1 secretion.^[1]

Why the TGF-β1 finding matters

TGF-β1 (transforming growth factor beta-1) is a key driver of fibrosis — the process that turns tissue damage into scar tissue rather than functional repair. Compounds that suppress TGF-β1 while promoting fibroblast activity are theoretically useful for wound healing that prioritizes regeneration over scarring. AHK-Cu's ability to do both simultaneously in cultured fibroblasts is what makes it mechanistically interesting, even at this early research stage.

In the same study, AHK-Cu was applied directly to human hair follicles maintained in culture and produced measurable elongation of the hair shaft — suggesting it may extend the anagen (active growth) phase of the hair cycle.^[1] That's a meaningful finding, but it's also an ex vivo result, meaning the follicles were removed from donors and kept alive in a dish. The jump from that to "works for hair loss in living people" is not a small one.

The copper is doing a lot of the work here. Copper ions are essential cofactors for enzymes involved in collagen crosslinking (lysyl oxidase), antioxidant defense (superoxide dismutase), and angiogenesis. The tripeptide backbone — alanine, histidine, lysine — acts as a carrier that chelates Cu²⁺ and delivers it in a bioavailable form to target cells. Histidine in particular is a strong copper-binding amino acid, which is why it appears at the center of most therapeutic copper peptide sequences.

Once the complex reaches fibroblasts, it appears to activate pathways that upregulate collagen synthesis and extracellular matrix (ECM) production — the structural scaffolding that gives skin its firmness and allows wound sites to rebuild properly.^[1] At the same time, the VEGF increase it produces matters for hair follicles specifically because follicles require dense vascularization to sustain active growth. Poor blood supply to the scalp is one of the features associated with androgenic alopecia.

The TGF-β1 suppression adds another layer. In wound healing, TGF-β1 drives myofibroblast differentiation — which is useful for closing wounds quickly but tends to produce scar tissue. A compound that keeps fibroblasts active while blunting the fibrotic signal is theoretically useful in contexts where you want tissue to regenerate rather than scar over. Whether AHK-Cu achieves this in living human tissue at concentrations achievable through topical application is still an open question.

The published evidence for AHK-Cu is thin by clinical standards — but what exists is specific enough to be worth examining carefully.

The central published study is a 2007 paper in Archives of Pharmacal Research by Park et al., which tested AHK-Cu on two systems: cultured human dermal fibroblasts and human hair follicles maintained ex vivo.^[1] In the fibroblast arm, AHK-Cu stimulated cell proliferation, increased VEGF secretion, and reduced TGF-β1 production compared to untreated controls. In the hair follicle arm, follicles treated with AHK-Cu showed greater elongation than controls over the observation period — a proxy for extended anagen phase duration.^[1]

That's the entirety of the peer-reviewed published record for AHK-Cu specifically. There are no Phase 1 safety trials, no Phase 2 efficacy trials, and no randomized controlled data in humans. The broader copper peptide literature — much of it centered on GHK-Cu — provides mechanistic context, but GHK-Cu data cannot be directly applied to AHK-Cu without independent confirmation.

What We Don't Know Yet

• Human clinical efficacy — The ex vivo hair follicle data is a starting point, not a conclusion. We have no randomized trial showing AHK-Cu improves hair density, wound healing, or skin quality in living people.
• Optimal topical concentration — No published dose-ranging studies exist for topical AHK-Cu formulations. Cosmetic products use varying concentrations without clinical validation behind those numbers.
• Systemic absorption — Copper peptides applied topically have limited transdermal penetration data. How much AHK-Cu actually reaches viable fibroblasts in the dermis from a surface application isn't established.
• Long-term safety — Copper accumulation with extended topical use hasn't been studied. Copper is essential at physiological levels but potentially toxic in excess; this hasn't been characterized for AHK-Cu specifically.
• Comparison to GHK-Cu — No head-to-head study has compared AHK-Cu and GHK-Cu directly. The structural difference may produce meaningful differences in efficacy or receptor interaction, but that's speculative without data.

There are no published clinical trials establishing an official dose for AHK-Cu. The compound is not approved for injection or systemic use, and no established injectable protocol exists in the peer-reviewed literature. Its documented administration route is topical.

No clinical dosing data exists

AHK-Cu dosing ranges for topical use are not derived from randomized clinical trials. Concentrations used in cosmetic and research formulations vary widely and have not been validated in human efficacy studies. If you're working with this compound in a research or clinical context, consult directly with a compounding pharmacist or dermatology researcher familiar with copper peptide formulations.

In cosmetic formulations, copper peptides including AHK-Cu are typically incorporated at concentrations ranging from 0.01% to 1% by weight — though dosing concentrations for AHK-Cu have not been established in human clinical trials; formulation concentrations are not verified from peer-reviewed sources — and the published ex vivo hair study does not report the exact concentration used in a way that translates directly to a topical formulation percentage.^[1] No published protocol guide establishes a validated range for AHK-Cu specifically.

If you're a researcher or formulator working with AHK-Cu, the study by Park et al. is the primary reference point for mechanism and biological activity, but it does not provide formulation guidance.^[1] Published dosing guidance for AHK-Cu beyond that study is limited — consult a practitioner or researcher who works with copper peptide formulations directly.

Human safety data for AHK-Cu doesn't exist in the published literature. No clinical trials have characterized its side effect profile. What follows is based on the general copper peptide class, general topical peptide safety considerations, and the absence of reported adverse events in the limited published research.

Topical use — general copper peptide class considerations:

• Skin irritation — Topical copper peptides can cause mild redness or irritation in sensitive skin, particularly at higher concentrations. Patch testing before full application is standard practice.
• Contact dermatitis — Rare but reported with copper-containing cosmetic ingredients. More likely in individuals with known metal sensitivities.
• Copper accumulation — Theoretical concern with extended, high-concentration topical use. Not characterized specifically for AHK-Cu; systemic copper toxicity from topical application is unlikely at cosmetic concentrations but unstudied for this compound.

What we genuinely don't know: There is no published adverse event data for AHK-Cu. The 2007 study that forms the primary published basis for this compound reported no cytotoxicity in fibroblast or dermal papilla cell cultures, but cell culture safety data does not predict human skin tolerability with confidence.^[1]

If you're using a topical product containing AHK-Cu and experience persistent redness, swelling, or skin breakdown, discontinue use and consult a dermatologist.

Research-only status — not approved for medical use

AHK-Cu is not FDA-approved for any medical indication. It is classified as a research compound in the United States. It is not available through licensed compounding pharmacies as a prescription drug, and there is no legal pathway for a physician to prescribe it as a therapeutic agent. It appears in some cosmetic and skincare formulations as an ingredient, which is a separate regulatory category from drug approval.

As a cosmetic ingredient, AHK-Cu is not subject to FDA pre-market approval — cosmetic ingredients don't require it. That means products containing AHK-Cu can be sold legally as skincare, but the manufacturer cannot make drug claims (e.g., "treats hair loss" or "heals wounds"). The distinction matters: a product can legally contain AHK-Cu, but it cannot legally be marketed as a treatment for a medical condition.

For researchers, AHK-Cu is available from peptide synthesis suppliers as a research-grade compound. As with all research chemicals, quality varies significantly by vendor.

If you're sourcing AHK-Cu as a research compound, quality control is the central issue. The peptide synthesis market has no consistent regulatory oversight, and purity varies substantially between suppliers.

What to look for:

• Third-party Certificate of Analysis (COA) — The COA should come from an independent analytical lab, not the vendor's own testing facility. Look for the lab name and contact information on the document itself.
• HPLC purity report — High-performance liquid chromatography purity should be ≥98% for research-grade peptides. Anything lower introduces uncertainty about what you're actually working with.
• Mass spectrometry confirmation — Confirms the compound's molecular weight matches the expected sequence. This rules out synthesis errors that HPLC alone might miss.
• Copper content verification — For copper peptide complexes specifically, the Cu²⁺ content should be confirmed analytically, not just assumed from the synthesis process. For copper peptide complexes used in research, analytical verification of Cu²⁺ content is recommended as a quality control measure, though clinical validation data in humans is not yet available.

Red flags:

• No COA or "in-house testing only" — The most common indicator of a vendor cutting corners on quality assurance.
• Price significantly below market — Solid-phase peptide synthesis and analytical testing cost money. Prices substantially below competitors usually reflect compromises somewhere in that process.
• No clear contact information or physical address — Legitimate research chemical suppliers are traceable businesses.

GHK-Cu is the reference compound for copper tripeptides in the research literature. It has decades of published research behind it, including studies on wound healing, skin remodeling, anti-inflammatory signaling, and hair follicle biology. AHK-Cu is structurally similar — both are tripeptides ending in histidine-lysine with a copper chelate — but AHK-Cu substitutes alanine for glycine at the N-terminus.

AHK-Cu vs. GHK-Cu: Key Differences

The honest comparison: GHK-Cu has a much larger published evidence base, which makes it easier to understand its behavior and limits. AHK-Cu's data is too sparse to say definitively whether the alanine substitution meaningfully changes efficacy. The 2007 study suggests it's biologically active through similar pathways, but that's one study.^[1]

If you're a researcher choosing between the two, GHK-Cu gives you more published precedent to work from. If you're specifically interested in AHK-Cu's distinct structural properties, Park et al. is your starting point and the gap in the literature is also the opportunity.